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Criteria for Acute Myocardial Infarction
The term myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
consistent with myocardial ischaemia. Under these conditions any one of the following criteria meets the diagnosis for
myocardial infarction:
• Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th
percentile of the upper reference limit (URL) together with evidence of myocardial ischaemia with at least one of
the following:
• Symptoms of ischaemia;
• ECG changes indicative of new ischaemia (new ST-T changes or new left bundle branch block [LBBB]);
• Development of pathological Q waves in the ECG;
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischaemia,
and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by coronary
angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood.
• For percutaneous coronary interventions (PCI) in patients with normal baseline troponin values, elevations of cardiac
biomarkers above the 99th percentile URL are indicative of peri-procedural myocardial necrosis. By convention,
increases of biomarkers greater than 3  99th percentile URL have been designated as defining PCI-related
myocardial infarction. A subtype related to a documented stent thrombosis is recognized.
• For coronary artery bypass grafting (CABG) in patients with normal baseline troponin values, elevations of cardiac
biomarkers above the 99th percentile URL are indicative of peri-procedural myocardial necrosis. By convention,
increases of biomarkers greater than 5  99th percentile URL plus either new pathological Q waves or new LBBB,
or angiographically documented new graft or native coronary artery occlusion, or imaging evidence of new loss of
viable myocardium have been designated as defining CABG-related myocardial infarction.
• Pathological findings of an acute myocardial infarction.
Criteria for Prior Myocardial Infarction
Any one of the following criteria meets the diagnosis for prior myocardial infarction:
• Development of new pathological Q waves with or without symptoms.
• Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a
non-ischaemic cause.
• Pathological findings of a healed or healing myocardial infarction.l
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dntroduction
yocardial infarction is a major cause of death and disabil-
ty worldwide. Coronary atherosclerosis is a chronic disease
ith stable and unstable periods. During unstable periods
ith activated inflammation in the vascular wall, patients
ay develop a myocardial infarction. Myocardial infarction
ay be a minor event in a lifelong chronic disease, it may
ven go undetected, but it may also be a major catastrophic
vent leading to sudden death or severe haemodynamic
eterioration. A myocardial infarction may be the first
anifestation of coronary artery disease, or it may occur,
epeatedly, in patients with established disease. Information
n myocardial infarction attack rates can provide useful data
egarding the burden of coronary artery disease within and
cross populations, especially if standardized data are col- (ected in a manner that demonstrates the distinction be-
ween incident and recurrent events. From the epidemio-
ogical point of view, the incidence of myocardial infarction
n a population can be used as a proxy for the prevalence of
oronary artery disease in that population. Furthermore, the
erm myocardial infarction has major psychological and
egal implications for the individual and society. It is an
ndicator of one of the leading health problems in the world,
nd it is an outcome measure in clinical trials and observa-
ional studies. With these perspectives, myocardial infarc-
ion may be defined from a number of different clinical,
lectrocardiographic, biochemical, imaging, and pathologi-
al characteristics.
In the past, a general consensus existed for the clinical
yndrome designated as myocardial infarction. In studies of
isease prevalence, the World Health Organization
WHO) defined myocardial infarction from symptoms,
E
m
a
s
r
e
d
p
s
t
S
t
(
f
C
i
r
a
S
C
1
m
E
C
i
t
b
e
t
t
f
d
S
c
i
t
o
t
g
s
m
o
2
r
i
t
l
b
r
l
m
d
A
v
a
m
G
g
d
W
o
i
a
r
r
d
f
d
F
o
C
T
m
p
a
t
s
e
r
f
i
m
d
a
t
d
t
E
P
M
c
g
b
c
o
t
i
m
b
o
s
l
2176 Thygesen et al. JACC Vol. 50, No. 22, 2007
ESC/ACCF/AHA/WHF Expert Consensus Document November 27, 2007:2173–95CG abnormalities, and enzymes. However, the develop-
ent of more sensitive and specific serological biomarkers
nd precise imaging techniques allows detection of ever
maller amounts of myocardial necrosis. Accordingly, cur-
ent clinical practice, health care delivery systems, as well as
pidemiology and clinical trials all require a more precise
efinition of myocardial infarction and a re-evaluation of
revious definitions of this condition.
It should be appreciated that over the years, while more
pecific biomarkers of myocardial necrosis became available,
he accuracy of detecting myocardial infarction has changed.
uch changes occurred when glutamine-oxaloacetic
ransaminase (GOT) was replaced by lactate dehydrogenase
LDH) and later by creatine kinase (CK) and the MB
raction of CK, i.e. CKMB activity and CKMB mass.
urrent, more specific, and sensitive biomarkers and imag-
ng methods to detect myocardial infarction are further
efinements in this evolution.
In response to the issues posed by an alteration in our
bility to identify myocardial infarction, the European
ociety of Cardiology (ESC) and the American College of
ardiology (ACC) convened a consensus conference in
999 in order to re-examine jointly the definition of
yocardial infarction (published in the year 2000 in the
uropean Heart Journal and Journal of the American
ollege of Cardiology [1]). The scientific and societal
mplications of an altered definition for myocardial infarc-
ion were examined from seven points of view: pathological,
iochemical, electrocardiographic, imaging, clinical trials,
pidemiological, and public policy. It became apparent from
he deliberations of the former consensus committee that
he term myocardial infarction should not be used without
urther qualifications, whether in clinical practice, in the
escription of patient cohorts, or in population studies.
uch qualifications should refer to the amount of myocardial
ell loss (infarct size), to the circumstances leading to the
nfarct (e.g. spontaneous or procedure related), and to the
iming of the myocardial necrosis relative to the time of the
bservation (evolving, healing, or healed myocardial infarc-
ion) (1).
Following the 1999 ESC/ACC consensus conference, a
roup of cardiovascular epidemiologists met to address the
pecific needs of population surveillance. This international
eeting, representing several national and international
rganizations, published recommendations in Circulation
003 (2). These recommendations addressed the needs of
esearchers engaged in long-term population trend analysis
n the context of changing diagnostic tools using retrospec-
ive medical record abstraction. Also considered was surveil-
ance in developing countries and out-of-hospital death,
oth situations with limited and/or missing data. These
ecommendations continue to form the basis for epidemio-
ogical research.
Given the considerable advances in the diagnosis and
anagement of myocardial infarction since the original
ocument was published, the leadership of the ESC, the tCC, and the American Heart Association (AHA) con-
ened, together with the World Heart Federation (WHF),
Global Task Force to update the 2000 consensus docu-
ent (1). As with the previous consensus committee, the
lobal Task Force was composed of a number of working
roups in order to refine the ESC/ACC criteria for the
iagnosis of myocardial infarction from various perspectives.
ith this goal in mind, the working groups were composed
f experts within the field of biomarkers, ECG, imaging,
nterventions, clinical investigations, global perspectives,
nd implications. During several Task Force meetings, the
ecommendations of the working groups were coordinated,
esulting in the present updated consensus document.
The Task Force recognizes that the definition of myocar-
ial infarction will be subject to a variety of changes in the
uture as a result of scientific advance. Therefore, this
ocument is not the final word on this issue for all time.
urther refinement of the present definition will doubtless
ccur in the future.
linical Features of Ischaemia
he term myocardial infarction reflects cell death of cardiac
yocytes caused by ischaemia, which is the result of a
erfusion imbalance between supply and demand. Isch-
emia in a clinical setting most often can be identified from
he patient’s history and from the ECG. Possible ischaemic
ymptoms include various combinations of chest, upper
xtremity, jaw, or epigastric discomfort with exertion or at
est. The discomfort associated with acute myocardial in-
arction usually lasts at least 20 min. Often, the discomfort
s diffuse, not localized, not positional, not affected by
ovement of the region, and it may be accompanied by
yspnoea, diaphoresis, nausea, or syncope.
These symptoms are not specific to myocardial ischaemia
nd can be misdiagnosed and thus attributed to gastroin-
estinal, neurological, pulmonary, or musculoskeletal disor-
ers. Myocardial infarction may occur with atypical symp-
oms, or even without symptoms, being detected only by
CG, biomarker elevations, or cardiac imaging.
athology
yocardial infarction is defined by pathology as myocardial
ell death due to prolonged ischaemia. Cell death is cate-
orized pathologically as coagulation and/or contraction
and necrosis, which usually evolves through oncosis, but
an result to a lesser degree from apoptosis. Careful analysis
f histological sections by an experienced observer is essen-
ial to distinguish these entities (1).
After the onset of myocardial ischaemia, cell death is not
mmediate but takes a finite period to develop (as little as 20
in or less in some animal models). It takes several hours
efore myocardial necrosis can be identified by macroscopic
r microscopic post-mortem examination. Complete necro-
is of all myocardial cells at risk requires at least 2–4 h or
onger depending on the presence of collateral circulation to
he ischaemic zone, persistent or intermittent coronary
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emia, pre-conditioning, and/or, finally, individual demand
or myocardial oxygen and nutrients. Myocardial infarctions
re usually classified by size: microscopic (focal necrosis),
mall (10% of the left ventricular [LV] myocardium),
oderate (10–30% of the LV myocardium), and large
30% of the LV myocardium), and by location. The
athological identification of myocardial necrosis is made
ithout reference to morphological changes in the coronary
rterial tree or to the clinical history (1).
Myocardial infarction can be defined pathologically as
cute, healing, or healed. Acute myocardial infarction is
haracterized by the presence of polymorphonuclear leuko-
ytes. If the time interval between the onset of the infarction
nd death is quite brief, e.g. 6 h, minimal or no polymor-
honuclear leukocytes may be seen. The presence of mono-
uclear cells and fibroblasts, and the absence of polymor-
honuclear leukocytes characterize healing infarction.
ealed infarction is manifested as scar tissue without
ellular infiltration. The entire process leading to a healed
nfarction usually takes at least 5–6 weeks. Reperfusion may
lter the macroscopic and microscopic appearance of the
ecrotic zone by producing myocytes with contraction
ands and large quantities of extravasated erythrocytes.
yocardial infarctions can be classified temporally from
linical and other features, as well as according to the
athological appearance, as evolving (6 h), acute (6 h–7
ays), healing (7–28 days), and healed (29 days and be-
ond). It should be emphasized that the clinical and
lectrocardiographic timing of the onset of an acute infarc-
ion may not correspond exactly with the pathological
iming. For example, the ECG may still demonstrate
volving ST-T changes and cardiac biomarkers may still be
levated (implying a recent infarct) at a time when patho-
ogically the infarction is in the healing phase (1).
Patients who suffer sudden cardiac death with or without
CG changes suggestive of ischaemia represent a challeng-
ng diagnostic group. Since these individuals die before
athological changes can develop in the myocardium, it is
ifficult to say with certainty whether these patients suc-
umbed to a myocardial infarction or to an ischaemic event
hat led to a fatal arrhythmia. The mode of death in these
ases is sudden, but the aetiology remains uncertain unless
he individual reported previous symptoms of ischaemic
eart disease prior to the cardiac arrest. Some patients with
r without a history of coronary disease may develop clinical
vidence of ischaemia, including prolonged and profound
hest pain, diaphoresis and/or shortness of breath, and
udden collapse. These individuals may die before blood
amples for biomarkers can be obtained, or these individuals
ay be in the lag phase before cardiac biomarkers can be
dentified in the blood. These patients may have suffered an
volving, fatal, acute myocardial infarction. If these patients
resent with presumably new ECG changes, for example
T elevation, and often with symptoms of ischaemia, they
hould be classified as having had a fatal myocardial infarc- nion even if cardiac biomarker evidence of infarction is
acking. Also, patients with evidence of fresh thrombus by
oronary angiography (if performed) and/or at autopsy
hould be classified as having undergone sudden death as a
esult of myocardial infarction.
linical Classification of Myocardial Infarction
linically the various types of myocardial infarction can be
lassified as shown in Table 1.
On occasion, patients may manifest more than one type
f myocardial infarction simultaneously or sequentially. It
hould also be noted that the term myocardial infarction
oes not include myocardial cell death associated with
echanical injury from coronary artery bypass grafting
CABG), for example ventricular venting, or manipulation
f the heart; nor does it include myocardial necrosis due to
iscellaneous causes, e.g. renal failure, heart failure, cardio-
ersion, electrophysiological ablation, sepsis, myocarditis,
ardiac toxins, or infiltrative diseases.
iomarker Evaluation
yocardial cell death can be recognized by the appearance
n the blood of different proteins released into the circula-
ion from the damaged myocytes: myoglobin, cardiac tro-
onin T and I, CK, LDH, as well as many others (3).
yocardial infarction is diagnosed when blood levels of
ensitive and specific biomarkers such as cardiac troponin or
KMB are increased in the clinical setting of acute myo-
ardial ischaemia (1). Although elevations in these biomar-
ers reflect myocardial necrosis, they do not indicate its
echanism (3,4). Thus, an elevated value of cardiac tropo-
able 1. Clinical Classification of Different Types of
yocardial Infarction
ype 1
Spontaneous myocardial infarction related to ischaemia due to a primary
coronary event such as plaque erosion and/or rupture, fissuring, or
dissection
ype 2
Myocardial infarction secondary to ischaemia due to either increased oxygen
demand or decreased supply, e.g. coronary artery spasm, coronary
embolism, anaemia, arrhythmias, hypertension, or hypotension
ype 3
Sudden unexpected cardiac death, including cardiac arrest, often with
symptoms suggestive of myocardial ischaemia, accompanied by
presumably new STelevation, or new LBBB, or evidence of fresh thrombus
in a coronary artery by angiography and/or at autopsy, but death
occurring before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood
ype 4a
Myocardial infarction associated with PCI
ype 4b
Myocardial infarction associated with stent thrombosis as documented by
angiography or at autopsy
ype 5
Myocardial infarction associated with CABGin in the absence of clinical evidence of ischaemia should
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ESC/ACCF/AHA/WHF Expert Consensus Document November 27, 2007:2173–95rompt a search for other aetiologies of myocardial necrosis,
uch as myocarditis, aortic dissection, pulmonary embolism,
ongestive heart failure, renal failure, and other examples
ndicated in Table 2.
The preferred biomarker for myocardial necrosis is car-
iac troponin (I or T), which has nearly absolute myocardial
issue specificity as well as high clinical sensitivity, thereby
eflecting even microscopic zones of myocardial necrosis (3).
n increased value for cardiac troponin is defined as a
easurement exceeding the 99th percentile of a normal
eference population (URL  upper reference limit). De-
ection of a rise and/or fall of the measurements is essential
o the diagnosis of acute myocardial infarction (6). The
bove-mentioned discriminatory percentile is designated as
he decision level for the diagnosis of myocardial infarction,
nd must be determined for each specific assay with appro-
riate quality control (7–9) Optimal precision (coefficient of
ariation [CV]) at the 99th percentile URL for each assay
hould be defined as 10%. Better precision (CV 10%)
llows for more sensitive assays (10,11). The use of assays
hat do not have independent validation of optimal preci-
ion (CV 10%) is not recommended. The values for the
9th percentile can be found on the International Federa-
ion for Clinical Chemistry website http://www.ifcc.org/
ndex.php?optioncom_remository&Itemid120&func
leinfo&id7.
Blood samples for the measurement of troponin should
e drawn on first assessment (often some hours after the
nset of symptoms) and 6–9 h later (12). An occasional
atient may require an additional sample between 12 and
4 h if the earlier measurements were not elevated and the
linical suspicion of myocardial infarction is high (12). To
stablish the diagnosis of myocardial infarction, one ele-
able 2. Elevations of Troponin in the Absence of Overt
schemic Heart Disease
ardiac contusion, or other trauma including surgery, ablation, pacing, etc.
ongestive heart failure—acute and chronic
ortic dissection
ortic valve disease
ypertrophic cardiomyopathy
achy- or bradyarrhythmias, or heart block
pical ballooning syndrome
habdomyolysis with cardiac injury
ulmonary embolism, severe pulmonary hypertension
enal failure
cute neurological disease, including stroke or subarachnoid haemorrhage
nfiltrative diseases, e.g. amyloidosis, haemochromatosis, sarcoidosis, and
scleroderma Inflammatory diseases, e.g. myocarditis or myocardial
extension of endo-/pericarditis
rug toxicity or toxins
ritically ill patients, especially with respiratory failure or sepsis
urns, especially if affecting 30% of body surface area
xtreme exertion
odified from Jaffe et al. (4) and French and White (5).ated value above the decision level is required. The dem- dnstration of a rising and/or falling pattern is needed to
istinguish background elevated troponin levels, e.g. pa-
ients with chronic renal failure (Table 2), from elevations in
he same patients which are indicative of myocardial infarc-
ion (6). However, this pattern is not absolutely required to
ake the diagnosis of myocardial infarction if the patient
resents 24 h after the onset of symptoms. Troponin
alues may remain elevated for 7–14 days following the
nset of infarction (4).
If troponin assays are not available, the best alternative is
KMB (measured by mass assay). As with troponin, an
ncreased CKMB value is defined as a measurement above
he 99th percentile URL, which is designated as the
ecision level for the diagnosis of myocardial infarction (9).
ender-specific values should be employed (9). The
KMB measurements should be recorded at the time of the
rst assessment of the patient and 6–9 h later in order to
emonstrate the rise and/or fall exceeding the 99th percen-
ile URL for the diagnosis of myocardial infarction. An
ccasional patient may require an additional diagnostic
ample between 12 and 24 h if the earlier CKMB measure-
ents were not elevated and the clinical suspicion of
yocardial infarction is high.
Measurement of total CK is not recommended for the
iagnosis of myocardial infarction, because of the large
keletal muscle distribution and the lack of specificity of this
nzyme.
einfarction
raditionally, CKMB has been used to detect reinfarction.
owever, recent data suggest that troponin values provide
imilar information (13). In patients where recurrent myo-
ardial infarction is suspected from clinical signs or symp-
oms following the initial infarction, an immediate measure-
ent of the employed cardiac marker is recommended. A
econd sample should be obtained 3–6 h later. Recurrent
nfarction is diagnosed if there is a 20% increase of the
alue in the second sample. Analytical values are considered
o be different if they are different by3 SDs of the variance
f the measures (14). For troponin, this value is 5–7% for
ost assays at the levels involved with reinfarction. Thus, a
0% change should be considered significant, i.e. over that
xpected from analytical variability itself. This value should
lso exceed the 99th percentile URL.
lectrocardiographic Detection of
yocardial Infarction
he ECG is an integral part of the diagnostic work-up of
atients with suspected myocardial infarction (1,2,15,16).
he acute or evolving changes in the ST-T waveforms and
he Q-waves when present potentially allow the clinician to
ate the event, to suggest the infarct-related artery, and to
stimate the amount of myocardium at risk. Coronary artery
ominance, size and distribution of arterial segments, col-
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tenoses can also impact ECG manifestations of myocardial
schaemia (17). The ECG by itself is often insufficient to
iagnose acute myocardial ischaemia or infarction since ST
eviation may be observed in other conditions such as acute
ericarditis, LV hypertrophy, LBBB, Brugada syndrome,
nd early repolarization patterns (18). Also Q-waves may
ccur due to myocardial fibrosis in the absence of coronary
rtery disease, as in, for example, cardiomyopathy.
CG Abnormalities of Myocardial Ischaemia That
ay Evolve to Myocardial Infarction
CG abnormalities of myocardial ischaemia or infarction
ay be inscribed in the PR segment, the QRS complex, and
he ST segment or T-waves. The earliest manifestations of
yocardial ischaemia are typical T-waves and ST segment
hanges (19,20). Increased hyper-acute T-wave amplitude
ith prominent symmetrical T-waves in at least two con-
iguous leads is an early sign that may precede the elevation
f the ST segment. Increased R-wave amplitude and width
giant R-wave with S-wave diminution) are often seen in
eads exhibiting ST elevation, and tall T-waves reflecting
onduction delay in the ischaemic myocardium (21). Tran-
ient Q-waves may be observed during an episode of acute
schaemia or rarely during acute myocardial infarction with
uccessful reperfusion (22).
Table 3 lists ECG criteria for the diagnosis of acute
yocardial ischaemia that may lead to infarction. The
-point is used to determine the magnitude of the ST
levation. J-point elevation in men decreases with increasing
ge; however, that is not observed in women, in whom
-point elevation is less than in men (23).
Contiguous leads means lead groups such as anterior
eads (V1–V6), inferior leads (II, III, and aVF), or lateral/
pical leads (I and aVL). More accurate spatial contiguity in
he frontal plane can be established by the Cabrera display:
VL, I, aVR, II, aVF, and III (24). Supplemental leads such
s V3R and V4R reflect the free wall of the right ventricle.
Although the criteria in Table 3 require that the ST shift
e present in two or more contiguous leads, it should be
oted that occasionally acute myocardial ischaemia may
reate sufficient ST segment shift to meet the criteria in one
ead but have slightly less than the required ST shift in an
djacent contiguous lead. Lesser degrees of ST displacement
able 3. ECG Manifestations of Acute Myocardial Ischaemia
in Absence of LVH and LBBB)
T elevation
New ST elevation at the J-point in two contiguous leads with the cut-off
points: 0.2 mV in men or 0.15 mV in women in leads V2–V3 and/or
0.1 mV in other leads
T depression and T-wave changes
New horizontal or down-sloping ST depression 0.05 mV in two contiguous
leads; and/or T inversion 0.1 mVin two contiguous leads with prominent
R-wave or R/S ratio 1r T-wave inversion in leads without prominent R-wave
*
gmplitude do not exclude acute myocardial ischaemia or
volving myocardial infarction.
ST elevation or diagnostic Q-waves in regional lead
roups are more specific than ST depression in localizing
he site of myocardial ischaemia or necrosis (25,26). How-
ver, ST depression in leads V1–V3 suggests myocardial
schaemia, especially when the terminal T-wave is positive
ST elevation equivalent), and may be confirmed by con-
omitant ST elevation 0.1 mV recorded in leads V7-V9
27,28). The term ‘posterior’ to reflect the basal part of the
V wall that lies on the diaphragm is no longer recom-
ended. It is preferable to refer to this territory as infero-
asal (29). In patients with inferior myocardial infarction it
s advisable to record right precordial leads (V3R and V4R)
eeking ST elevation in order to identify concomitant right
entricular infarction (30).
During an acute episode of chest discomfort, pseudo-
ormalization of previously inverted T-waves may indicate
cute myocardial ischaemia. Pulmonary embolism, intracra-
ial processes, or peri-/myocarditis may also result in ST-T
bnormalities and should be considered (false positives) in
he differential diagnosis.
The diagnosis of myocardial infarction is difficult in the
resence of LBBB even when marked ST-T abnormalities
r ST elevation are present that exceed standard criteria
31,32). A previous ECG may be helpful to determine the
resence of acute myocardial infarction in this setting. In
atients with right bundle branch block (RBBB), ST-T
bnormalities in leads V1–V3 are common, making it
ifficult to assess the presence of ischaemia in these leads;
owever, when ST elevation or Q-waves are found, myo-
ardial ischaemia or infarction should be considered. Some
atients present with ST elevation or new LBBB, and suffer
udden cardiac death before cardiac biomarkers become
bnormal or pathological signs of myocardial necrosis be-
ome evident at autopsy. These patients should be classified
s having had a fatal myocardial infarction.
rior Myocardial Infarction
s shown in Table 4, Q-waves or QS complexes in the
bsence of QRS confounders are usually pathognomonic of
prior myocardial infarction (33–35). The specificity of the
CG diagnosis for myocardial infarction is greatest when
-waves occur in several leads or lead groupings. ST
eviations or T-waves alone are non-specific findings for
able 4. ECG Changes Associated With Prior Myocardial
nfarction
ny Q-wave in leads V2–V3 0.02 s or QS complex in leads V2 and V3
-wave 0.03 s and 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or
V4–V6 in any two leads of a contiguous lead grouping (I, aVL,V6; V4–V6; II, III,
and aVF)*
-wave 0.04 s in V1–V2 and R/S 1 with a concordant positive T-wave in the
absence of a conduction defectThe same criteria are used for supplemental leads V7–V9, and for the Cabrera frontal plane lead
rouping.
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ccur in the same leads as the Q-waves, the likelihood of
yocardial infarction is increased. For example, minor
-waves 0.02 and 0.03 s that are 0.1 mV deep are
uggestive of prior infarction if accompanied by inverted
-waves in the same lead group.
Other validated myocardial infarction-coding algorithms,
uch as the Minnesota code, Novacode, and WHO
ONICA, define Q-wave depth on the basis of depth,
idth, and ratio of R-wave amplitude, such as Q-wave
epth at least one-third or one-fifth of R-wave amplitude,
nd have been used extensively in epidemiological studies
nd clinical trials (36,37).
onditions That Confound the ECG Diagnosis of
yocardial Infarction
QS complex in lead V1 is normal. A Q-wave0.03 s and
1/4 of the R-wave amplitude in lead III is normal if the
rontal QRS axis is between 30 and 0°. The Q-wave may
lso be normal in aVL if the frontal QRS axis is between 60
nd 90°. Septal Q-waves are small non-pathological
-waves 0.03 s and 1/4 of the R-wave amplitude in
eads I, aVL, aVF, and V4–V6. Pre-excitation, obstructive or
ilated cardiomyopathy, LBBB, RBBB, left anterior hemi-
lock, left and right ventricular hypertrophy, myocarditis,
cute cor pulmonale, or hyperkalaemia may be associated
ith Q/QS complexes in the absence of myocardial infarc-
ion. ECG abnormalities that simulate myocardial isch-
emia or infarction are presented in Table 5.
einfarction
he ECG diagnosis of reinfarction following the initial
nfarction may be confounded by the initial evolutionary
CG changes. Reinfarction should be considered when ST
levation 0.1 mV reoccurs in a patient having a lesser
egree of ST elevation or new pathognomonic Q waves, in
t least two contiguous leads, particularly when associated
able 5. Common ECG Pitfalls in Diagnosing
yocardial Infarction
alse positives
Benign early repolarization
LBBB
Pre-excitation
Brugada syndrome
Peri-/myocarditis
Pulmonary embolism
Subarachnoid haemorrhage
Metabolic disturbances such as hyperkalaemia
Failure to recognize normal limits for J-point displacement
Lead transposition or use of modified Mason–Likar configuration (24)
Cholecystitis
alse negatives
Prior myocardial infarction with Q-waves and/or persistent ST elevation
Paced rhythm
LBBBaith ischaemic symptoms for 20 min or longer. The
e-elevation of the ST segment can, however, also be seen in
hreatening myocardial rupture and should lead to addi-
ional diagnostic work-up. ST depression or LBBB on their
wn should not be considered valid criteria for myocardial
nfarction.
oronary Revascularization
CG abnormalities during or after percutaneous coronary
ntervention (PCI) are similar to those seen during sponta-
eous myocardial infarction. In patients who have under-
one CABG, new ST-T abnormalities are common but not
ecessarily diagnostic of myocardial ischaemia (38). How-
ver, when new pathological Q waves (Table 4) appear in
erritories other than those identified before surgery, myo-
ardial infarction should be considered, particularly if asso-
iated with elevated biomarkers, new wall motion abnor-
alities, or haemodynamic instability.
maging Techniques
on-invasive imaging plays many roles in patients with
nown or suspected myocardial infarction, but this section
oncerns only its role in the diagnosis and characterization
f infarction. The underlying rationale is that regional
yocardial hypoperfusion and ischaemia lead to a cascade of
vents including myocardial dysfunction, cell death, and
ealing by fibrosis. Important imaging parameters are there-
ore perfusion, myocyte viability, myocardial thickness,
hickening, and motion, and the effects of fibrosis on the
inetics of radiolabelled and paramagnetic contrast agents.
Commonly used imaging techniques in acute and chronic
nfarction are echocardiography, radionuclide ventriculog-
aphy, myocardial perfusion scintigraphy (MPS), and mag-
etic resonance imaging (MRI). Positron emission tomog-
aphy (PET) and X-ray computed tomography (CT) are
ess common. There is considerable overlap in their capa-
ilities, but only the radionuclide techniques provide a direct
ssessment of myocardial viability because of the properties
f the tracers used. Other techniques provide indirect
ssessments of myocardial viability, such as myocardial
unction from echocardiography or myocardial fibrosis from
RI.
chocardiography
chocardiography is an excellent real-time imaging tech-
ique with moderate spatial and temporal resolution. Its
trength is the assessment of myocardial thickness, thicken-
ng, and motion at rest. This can be aided by tissue Doppler
maging. Echocardiographic contrast agents can improve
ndocardial visualization, but contrast studies are not yet
ully validated for the detection of myocardial necrosis,
lthough early work is encouraging (39).
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everal radionuclide tracers allow viable myocytes to be
maged directly, including thallium-201, technetium-99m
IBI, tetrofosmin, and (18F)2-fluorodeoxyglucose (FDG)
40–42). The strength of the techniques are that they are
he only commonly available direct methods of assessing
iability, although the relatively low resolution of the images
isadvantages them for detecting small areas of infarction (43).
he common single photon-emitting radio-pharmaceuticals
re also tracers of myocardial perfusion and so the tech-
iques readily detect areas of infarction and inducible
er-fusion abnormalities. ECG-gated imaging provides a
eliable assessment of myocardial motion, thickening, and
lobal function (44,45).
agnetic Resonance Imaging
ardiovascular MRI has high spatial resolution and mod-
rate temporal resolution. It is a well-validated standard for
he assessment of myocardial function and has, in theory,
imilar capability to echocardiography in suspected acute
nfarction. It is, however, more cumbersome in an acute
etting and is not commonly used. Paramagnetic contrast
gents can be used to assess myocardial perfusion and the
ncrease in extracellular space associated with the fibrosis of
hronic infarction. The former is not yet fully validated in
linical practice, but the latter is well validated and can play
n important role in the detection of infarction (46,47).
-Ray Computed Tomography
nfarcted myocardium is initially visible to CT as a focal area of
ecreased LV enhancement, but later imaging shows hyper-
nhancement as with late gadolinium imaging by MRI
48,49). This finding is clinically relevant because contrast-
nhanced CT may be performed for suspected embolism and
ortic dissection, conditions with clinical features that overlap
ith those of acute myocardial infarction.
pplication in the Acute Phase of
yocardial Infarction
maging techniques can be useful in the diagnosis of
yocardial infarction because of the ability to detect wall
otion abnormalities in the presence of elevated cardiac
io-markers. If for some reason biomarkers have not been
easured or may have normalized, demonstration of new
oss of myocardial viability alone in the absence of non-
schaemic causes meets the criteria for myocardial infarc-
ion. However, if biomarkers have been measured at appro-
riate times and are normal, the determinations of these
ake precedence over the imaging criteria.
Echocardiography provides assessment of many non-
schaemic causes of acute chest pain such as peri-
yocarditis, valvular heart disease, cardiomyopathy, pulmo-
ary embolism, or aortic dissection. Echocardiography is
he imaging technique of choice for detecting complications
f acute infarction including myocardial free wall rupture,
cute ventricular septal defect, and mitral regurgitation wecondary to papillary muscle rupture or ischaemia. How-
ver, echocardiography cannot distinguish regional wall
otion abnormalities due to myocardial ischaemia from
nfarction.
Radionuclide assessment of perfusion at the time of
atient presentation can be performed with immediate
racer injection and imaging that can be delayed for up to
everal hours. The technique is interpreter dependent,
lthough objective quantitative analysis is available. ECG
ating provides simultaneous information on LV function.
An important role of acute echocardiography or radio-
uclide imaging is in patients with suspected myocardial
nfarction and a non-diagnostic ECG. A normal echocar-
iogram or resting ECG-gated scintigram has a 95–98%
egative predictive value for excluding acute infarction
50–54). Thus, imaging techniques are useful for early
riage and discharge of patients with suspected myocardial
nfarction (55,56).
A regional myocardial wall motion abnormality or loss of
ormal thickening may be caused by acute myocardial
nfarction or by one or more of several other ischaemic
onditions including old infarction, acute ischaemia, stun-
ing, or hibernation. Non-ischaemic conditions such as
ardiomyopathy and inflammatory or infiltrative diseases
an also lead to regional loss of viable myocardium or
unctional abnormality, and so the positive predictive value
f imaging techniques is not high unless these conditions
an be excluded and unless a new abnormality is detected or
an be presumed to have arisen in the setting of other
eatures of acute myocardial infarction.
pplication in the Healing or Healed Phase of
yocardial Infarction
maging techniques are useful in myocardial infarction for
nalysis of LV function, both at rest and during dynamic
xercise or pharmacological stress, to provide an assessment
f remote inducible ischaemia. Echocardiography and
adio-nuclide techniques, in conjunction with exercise or
harmacological stress, can identify ischaemia and myocar-
ial viability. Non-invasive imaging techniques can diag-
ose healing or healed infarction by demonstrating regional
all motion, thinning, or scar in the absence of other causes.
The high resolution of contrast-enhanced MRI means that
reas of late enhancement correlate well with areas of fibrosis
nd thereby enable differentiation between transmural and
ubendocardial scarring (57). The technique is therefore po-
entially valuable in assessing LV function and areas of viable
nd hence potentially hibernating myocardium.
yocardial Infarction Associated With
evascularization Procedures
eri-procedural myocardial infarction is different from
pontaneous infarction, because the former is associated
ith the instrumentation of the heart that is required during
m
C
a
i
m
l
t
n
s
d
r
z
u
a
t
o
m
n
(
r
a
p
t
c
i
t
r
m
(
s
e
h
p
d
e
r
D
W
I
p
a
p
m
p
t
P
a
r
t
i
t
t
i
n
i
d
t
f
t
i
a
t
f
D
W
A
m
b
T
C
l
p
l
w
t
m
t
t
a
o
s
b
fi
d
w
L
c
o
a
i
D
C
A
o
i
a
I
c
i
t
a
2182 Thygesen et al. JACC Vol. 50, No. 22, 2007
ESC/ACCF/AHA/WHF Expert Consensus Document November 27, 2007:2173–95echanical revascularization procedures by either PCI or
ABG. Multiple events that can lead to myocardial necrosis
re taking place, often in combination, during both types of
ntervention (58–61). While some loss of myocardial tissue
ay be unavoidable during procedures, it is likely that
imitation of such damage is beneficial to the patient and
heir prognosis (62).
During PCI, myocardial necrosis may result from recog-
izable peri-procedural events, alone or in combination,
uch as side-branch occlusion, disruption of collateral flow,
istal embolization, coronary dissection, slow flow or no-
eflow phenomenon, and microvascular plugging. Emboli-
ation of intracoronary thrombus or atherosclerotic partic-
late debris cannot be entirely prevented despite current
ntithrombotic and antiplatelet adjunctive therapy or pro-
ection devices. Such events induce extensive inflammation
f non-infarcted myocardium surrounding small islets of
yocardium necrosis (63–67). New areas of myocardial
ecrosis have been demonstrated by MRI following PCI
68). A separate subcategory of myocardial infarction is
elated to stent thrombosis as documented by angiography
nd/or autopsy.
During CABG, numerous additional factors can lead to
eri-procedural necrosis. These include direct myocardial
rauma from sewing needles or manipulation of the heart,
oronary dissection, global or regional ischaemia related to
nadequate cardiac protection, microvascular events related
o reperfusion, myocardial damage induced by oxygen free
adical generation, or failure to reperfuse areas of the
yocardium that are not subtended by graftable vessels
69–71). MRI studies suggest that most necrosis in this
etting is not focal, but diffuse and localized to the sub-
ndocardium (72) Some clinicians and clinical investigators
ave preferred using CKMB for the diagnosis of peri-
rocedural infarction because of a substantial amount of
ata relating CKMB elevations to prognosis (73,74). How-
ver, an increasing number of studies using troponins in that
espect have emerged (59,75).
iagnostic Criteria for Myocardial Infarction
ith PCI
n the setting of PCI, the balloon inflation during a
rocedure almost always results in ischaemia whether or not
ccompanied by ST-T changes. The occurrence of
rocedure-related cell necrosis can be detected by measure-
ent of cardiac biomarkers before or immediately after the
rocedure, and again at 6–12 and 18–24 h (76,77). Eleva-
ions of biomarkers above the 99th percentile URL after
CI, assuming a normal baseline troponin value, are indic-
tive of post-procedural myocardial necrosis. There is cur-
ently no solid scientific basis for defining a biomarker
hreshold for the diagnosis of peri-procedural myocardial
nfarction. Pending further data, and by arbitrary conven-
ion, it is suggested to designate increases more than three
imes the 99th percentile URL as PCI-related myocardial
nfarction (type 4a). tIf cardiac troponin is elevated before the procedure and
ot stable for at least two samples 6 h apart, there are
nsufficient data to recommend biomarker criteria for the
iagnosis of peri-procedural myocardial infarction (77). If
he values are stable or falling, criteria for reinfarction by
urther measurement of biomarkers together with the fea-
ures of the ECG or imaging can be applied.
A separate subcategory of myocardial infarction (type 4b)
s related to stent thrombosis as documented by angiography
nd/or autopsy. Although iatrogenic, myocardial infarction
ype 4b with verified stent thrombosis must meet the criteria
or spontaneous myocardial infarction as well.
iagnostic Criteria for Myocardial Infarction
ith CABG
ny increase of cardiac biomarkers after CABG indicates
yocyte necrosis, implying that an increasing magnitude of
iomarker is likely to be related to an impaired outcome.
his has been demonstrated in clinical studies employing
KMB where elevations five, 10 and 20 times the upper
imit of normal after CABG were associated with worsened
rognosis (73,78,79). Likewise, the increase of troponin
evels after CABG indicates necrosis of myocardial cells,
hich predicts a poor outcome, in particular when elevated
o the highest quartile or quintile of the troponin measure-
ents (59,75).
Unlike the prognosis, scant literature exists concerning
he use of biomarkers for defining myocardial infarction in
he setting of CABG. Therefore, biomarkers cannot stand
lone in diagnosing myocardial infarction (type 5). In view
f the adverse impact on survival observed in patients with
ignificant biomarker elevations, this Task Force suggests,
y arbitrary convention, that biomarker values more than
ve times the 99th percentile of the normal reference range
uring the first 72 h following CABG, when associated
ith the appearance of new pathological Q-waves or new
BBB, or angiographically documented new graft or native
oronary artery occlusion, or imaging evidence of new loss
f viable myocardium, should be considered as diagnostic of
CABG-related myocardial infarction (type 5 myocardial
nfarction).
efinition of Myocardial Infarction in
linical Investigations
universal definition for myocardial infarction would be
f great benefit to future clinical studies in this area since
t will allow for trial-to-trial comparisons as well as
ccurate meta-analyses involving multiple investigations.
n clinical trials, myocardial infarction may be an entry
riterion or an end-point. The definition of myocardial
nfarction employed in these trials will thus determine
he characteristics of patients entering the studies as well
s the number of outcome events. In recent investiga-
ions, different infarct definitions have been employed,
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Consistency among investigators and regulatory au-
horities with regard to the definition of myocardial
nfarction used in clinical investigations is essential. The
ask Force strongly encourages trialists to employ the
efinition described in this document. Furthermore, in-
estigators should ensure that a trial provides compre-
ensive data for the various types of myocardial infarction
e.g. spontaneous, peri-procedural) and includes the em-
loyed decision limits for myocardial infarction of the
ardiac biomarkers in question. All data should be made
vailable to interested individuals in published format or
n a website. Data concerning infarctions should be
vailable in a form consistent with the current revised
efinitions of myocardial infarction. This does not nec-
ssarily restrict trialists to a narrow end-point definition,
ut rather ensures that across all future trials access to
omparable data exists, thereby facilitating cross-study
nalyses. The recommendations put forward in this
ection are not detailed and should be supplemented by
areful protocol planning and implementation in any
linical trial.
The Task Force strongly endorses the concept of the
ame decision limit for each biomarker employed for myo-
ardial infarction types 1 and 2, and, likewise, the same
igher three- and five-fold decision limits in the setting of
yocardial infarction types 4a and 5, respectively (78–80)
Tables 6 and 7). In clinical trials, as in clinical practice,
easurement of cardiac troponin T or I is preferred over
able 6. Classification of the Different Types of Myocardial Infa
pplied Cardiac Biomarker
Multiples  99%
MI type 1
(spontaneous)
MI type 2
(secondary)
MI type 3*
(sudden death)
–2 
–3 
–5 
–10 
10 
otal number
Biomarkers are not available for this type of myocardial infarction since the patients expired bef
f biomarker values should be reported. The dark grey areas represent biomarker elevations belo
efinition chosen in a clinical trial, all data should be provided. All boxes in the table should be
able 7. Sample Clinical Trial Tabulation of Randomized
atients by Types of Myocardial Infarction
Treatment A Treatment B
Types of MI Number of patients Number of patients
I type 1
I type 2
I type 3
I type 4a
I type 4b
I type 5
otal numbereasurement of CKMB or other biomarkers for the diag-
osis of myocardial infarction. Assessment of the quantity
f myocardial damage (infarct size) is also an important trial
nd-point. Although the specific measurements vary de-
ending on the assay and whether cardiac troponin T or I is
sed, in most studies troponin values correlate better with
adionuclide- and MRI-determined infarct size than do CK
nd CKMB (81–83).
The use of cardiac troponins will undoubtedly increase
he number of events recorded in a particular investigation
ecause of increased sensitivity for detecting infarction
84–87). Ideally, data should be presented so that future
linical investigations or registries can translate the myocar-
ial infarction end-point chosen in one study into the
nd-point of another study. Thus, measurements should be
resented in a uniform manner to allow independent judge-
ent and comparison of the clinical end-points. Further-
ore, this Task Force suggests that data be reported as
ultiples of the 99th percentile URL of the applied biomar-
er, enabling comparisons between various classes and
everity of the different types of myocardial infarction as
ndicated in Tables 6 and 7.
It is recommended that within a clinical trial all
nvestigators whenever possible should employ the same
ssay in order to reduce the inter-assay variability, and,
ven better, the latter could be reduced to zero by
pplication of a core laboratory using the same assay for
ll measurements.
In the design of a study, investigators should specify the
xpected effect of the new treatment under investigation.
actors that should be considered include:
Assessment of the incidence of spontaneous myocardial
infarction (type 1) and infarction related to myocardial
oxygen supplies and demand (type 2) in treated patients
vs. control subjects.
Assessment of the incidence of sudden death related to
myocardial infarction when applying the suggested cri-
teria (type 3).
Assessment of the incidence of procedure-related myo-
cardial infarctions and biomarker elevations (PCI, types
n According to Multiples of the 99th Percentile URL of the
I type 4a†
(PCI)
MI type 4b
(stent thrombosis)
MI type 5†
(CABG)
Total
number
marker determination could be performed. †For the sake of completeness, the total distribution
ecision limit used for these types of myocardial infarction. Irrespective of the specific end-point
eted, including the shaded areas.rctio
M
ore bio4a and 4b; and CABG, type 5).
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yocardial Infarction
volution of the definition of a specific diagnosis such as
yocardial infarction has a number of implications for
ndividual citizens as well as for society at large. The process
f assigning a specific diagnosis to a patient should be
ssociated with a specific value for the patient. The re-
ources spent on recording and tracking a particular diag-
osis must also have a specific value to society in order to
ustify the effort. A tentative or final diagnosis is the basis for
dvice about further diagnostic testing, treatment, lifestyle
hanges, and prognosis for the patient. The aggregate of
atients with a particular diagnosis is the basis for health
are planning and policy, and resource allocation.
One of the goals of good clinical practice is to reach a
efinitive and specific diagnosis, which is supported by
urrent scientific knowledge. The approach to the definition
f myocardial infarction outlined in this document meets
his goal. In general, the conceptual meaning of the term
yocardial infarction has not changed, although new sen-
itive diagnostic methods have been developed to diagnose
his entity. Thus, the current diagnosis of acute myocardial
nfarction is a clinical diagnosis based on patient symptoms,
CG changes, and highly sensitive biochemical markers, as
ell as information gleaned from various imaging tech-
iques. However, it is important to characterize the extent
f the infarct as well as residual LV function and the severity
f coronary artery disease, rather than merely making a
iagnosis of myocardial infarction. The information con-
eyed about the patient’s prognosis and ability to work
equires more than just the mere statement that the patient
as suffered an infarct. The multiple other factors just
entioned are also required so that appropriate social,
amily, and employment decisions can be made. A number
f risk scores have been developed predicting post-infarction
rognosis. The classification of the various other prognostic
ntities associated with myocardial necrosis should lead to a
econsideration of the clinical coding entities currently
mployed for patients with the myriad conditions that can
ead to myocardial necrosis with consequent elevation of
iomarkers.
Many patients with myocardial infarction die suddenly.
ifficulties in definition of sudden and out-of-hospital
eath make attribution of the cause of death variable among
hysicians, regions, and countries. For example, out-of-
ospital death is generally ascribed to ischaemic heart
isease in the USA but to stroke in Japan. These arbitrary
nd cultural criteria need re-examination.
It is important that any revised criteria for the definition
f myocardial infarction involve comparability of this defi-
ition over time so that adequate trend data can be
btained. Furthermore, it is essential to ensure widespread
vailability and standard application of the measures in
rder to ensure comparability of data from various geo- mraphic regions. Shift in criteria resulting in a substantial
ncrease or decrease in case identification will have signifi-
ant health resource and cost implications (86,87). More-
ver, an increase in sensitivity of the criteria for myocardial
nfarction might entail negative consequences for some
atients who are not currently labelled as having had an
nfarction. On the other hand, increasing diagnostic sensi-
ivity for myocardial infarction can have a positive impact
or a society:
Increasing the sensitivity of diagnostic criteria for myo-
cardial infarction will result in more cases identified in a
society, thereby allowing appropriate secondary preven-
tion.
Increasing the specificity of diagnostic criteria for myo-
cardial infarction will result in more accurate diagnosis
but will not exclude the presence of coronary artery
disease, the cases of which may benefit from secondary
prevention.
It should be appreciated that the agreed modification of
he definition of myocardial infarction may be associated
ith consequences for the patients and their families with
espect to psychological status, life insurance, professional
areer, as well as driving and pilot licences. Also the
iagnosis is associated with societal implications as to
iagnosis-related coding, hospital reimbursement, mortality
tatistics, sick leave, and disability attestation.
In order to meet this challenge, physicians must be
dequately informed of the altered diagnostic criteria. Ed-
cational materials will need to be created and treatment
uidelines must be appropriately adapted. Professional so-
ieties should take steps to facilitate the rapid dissemination
f the revised definition to physicians, other health care
rofessionals, administrators, and the general public.
lobal Perspectives of the Redefinition of
yocardial Infarction
ardiovascular disease is a global health problem. Approx-
mately one-third of persons in the world die of cardiovas-
ular disease, largely coronary artery disease and stroke, and
0% of these deaths from cardiovascular disease occur in
eveloping countries. The greater proportion of deaths is
ue to heart disease and specifically coronary heart disease,
f which myocardial infarction is a major manifestation.
ince it is difficult to measure the prevalence of coronary
rtery disease in a population, the incidence of myocardial
nfarction may be used as a proxy, provided that a consistent
efinition is used when different populations, countries, or
ontinents are being compared.
The changes in the definition of myocardial infarction
ave critical consequences for less developed and developing
ountries. In many countries, the resources to apply the new
efinition may not be available in all hospitals. However,
any developing countries already do have medical facilities
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yocardial infarction. In the context of the overall cost for
patient with myocardial infarction, the expense associated
ith a troponin assay would not be excessive and should be
conomically affordable in many hospitals in developing
ountries, particularly those where infarcts are frequent
vents. The necessary equipment, staff training, and running
osts may be lacking in some regions, but certainly not in
thers. In less advantaged hospitals, the diagnosis of myo-
ardial infarction may depend mostly on clinical signs and
ymptoms coupled with less sophisticated biomarker anal-
ses. Some of these institutions may only have access to CK
nd its isoenzymes at the present time. The redefinition
rises from and is compatible with the latest scientific
nowledge and with advances in technology, particularly
ith regard to the use of biomarkers, high quality electro-
ardiography, and imaging techniques. The definition can
nd should be used by developed countries immediately, and
y developing countries as quickly as resources become
vailable.
The change in the definition of myocardial infarction will
ave a substantial impact on the identification, prevention,
nd treatment of cardiovascular disease throughout the
orld. The new definition will impact epidemiological data
rom developing countries relating to prevalence and inci-
ence. The simultaneous and continuing use of the older
HO definition for some years would allow a comparison
etween data obtained in the past and data to be acquired in
he future employing the newer biomarker approach. Cul-
ural, financial, structural, and organizational problems in
he different countries of the world in diagnosis and therapy
f acute myocardial infarction will require ongoing investi-
ation. It is essential that the gap between therapeutic and
iagnostic advances be addressed in this expanding area of
ardiovascular disease.
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● Sanofi-Aventis
● Schering-Plough
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● Procter & Gamble
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● Schering-Plough
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Company
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Johnson Company
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● Medtronic
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● Cordis, a Johnson &
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● Cordis, a Johnson
& Johnson
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● Medtronic
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● Amgen
● Amylin Pharmaceuticals, Inc.
● Anadys
● ANGES MG, Inc.
● Arginox Pharmaceuticals†
● Angiometrx, Inc.
● Ark Therapeutics, Ltd.
● Astellas Pharma US, Inc.
● Astra Hassle
● AstraZeneca†
● Atritech
● Aventis†
● Avion Flumist
● Baxter
● Bayer AG
● Bayer Corp.
● Berlex
● Biocompatibles, Ltd.
● Biogen
● Bioheart
● Biomarin
● Biosense Webster, Inc.
● Biosite
● Bio Technology General
● Biotronik
● Boehringer Ingelheim
● Bristol-Myers
Squibb
None None None Educational
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● Merck/Schering-
Plough Venture*
● Portola
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● Sanofi-Aventis
● Schering-Plough
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● Boston MedTech Advisors
● Boston Scientific
● Bracco Diagnostics
● Bristol-Myers Squibb†
● CanAm Bioresearch†
● Cardiac Science, Inc.
● Cardio Thoracic Systems
● CardioDynamics International
● CardioKinetix, Inc.
● Celsion Corp.
● Centocor
● Chugai Pharmaceuticals
● Cierra, Inc.
● Coley Pharma Group
● Conor Medsystems, Inc.
● Corautus Genetics, Inc.
● Cordis
● Corgentech
● Corvalent Group
● Critical Therapeutics, Inc.
● CryoVascular System, Inc.
● Cubist Pharmaceuticals
● CV Therapeutics, Inc.
● Cytokinetics, Inc.
● Dade Behring
● Daiichi
● Decide Genetics
● Dyax
● Echosens, Inc.
● Elipse Surg Tech
● Edwards Lifesciences
● Eisai
● Enzon Pharmaceutical
● EPI-Q, Inc.
● Ev3, Inc.
● Evalve, Inc.
● First Circle Medical, Inc.
● First Horizon
● Flow Cardia, Inc.
● Fox Hollow Pharmaceutical
● Fujisawa
● Genentech
● General Electric Healthcare
● General Electric Medical
Systems
● Genzyme Corporation
● Getz Bros., Co., Inc.
● Gilead
● GlaxoSmithKline
● Guidant
● Guilford Pharmaceuticals
● Heartscape Technologies, Inc.
● Hoffman-LaRoche
● Human Genome Sciences
● Humana
● IDB Medical
● Idenix Pharmaceuticals, Inc.
● Idun Pharmaceutical, Inc.
● Immunex
● Idenix Pharmaceutical
● INFORMD, Inc.
● InfraReDx
● Inhibitex
● INO Therapeutics, Inc.
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● Inspire Pharm
● Integrated Therapeutics
Group
● InterMune Pharmaceuticals
● Inverness Medical
Innovations
● ISIS Pharmaceuticals
● Johnson & Johnson
● Jomed, Inc.
● KAI Pharmaceuticals†
● Kerberos Proximal, Inc.
● King Pharmaceuticals
● Kuhera Chemical Co.
● Lilly
● Lumen Biomedical
● Medacoustics
● Medicure†
● Medi-Flex, Inc.
● Med Immune
● Medtronic, Inc.
● Merck
● Merck/Schering-Plough
Venture†
● MicroMed Tech, Inc.
● Microphage, Inc.
● Millenium Pharmaceutical†
● Mitsubishi
● Momenta Pharmaceuticals
● Mycosol, Inc.
● Myogen
● NABI
● Neuron Pharmaceuticals
● NitroMed
● NovaCardia, Inc.
● Novartis*
● Organon International
● Ortho Biotech
● Osiris Therapeutics, Inc.
● Otsuka America
Pharmaceutical, Inc.
● Pathway Medical Tech
● PDL bioPharma
● Pfizer
● Pharmanetics
● Pfizer
● Portola Pharmaceutical†
● Proctor and Gamble
● Prometheus
● Radiant
● Recom Managed Systems
● Regado Biosciences, Inc.†
● Reliant Pharma
● Roche Diagnostic Corp.
● Salix Pharmaceuticals
● Sanofi Pasteur
● Sanofi-Aventis†
● Sanofi-Synthelabo
● Schering-Plough†
● SciClone Pharmaceuticals
● Scios
● Searle
● Sicel Technologies
● Siemens
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● Social Scientific Systems, Inc.
Spectranetics
● Summit
● Suneis
● TAP Pharmaceutical
Products, Inc.
● Terumo Corporation
● The Medicines Company
● Theravance
● TherOx, Inc.
● Titan Pharmaceuticals, Inc.
● Valeant Pharmaceuticals
● Valentis, Inc.
● Vascular Solutions, Inc.
● Velocimed
● Veridex
● Vertex Pharmaceuticals
● Viasys Healthcare, Inc.
● Vicuron Pharma
● Wyeth
● Wyeth-Ayerst
● Xoma
● Xsira Pharmaceuticals
● XTL Biopharmaceuticals
● Yamanouchi
len N. Levine None None
ichael Lim None None
arco A.
Martı´nez-Rios
None None
oao Morals None ● AstraZeneca
avid Morrow ● Bayer Diagnostics
● Beckman Coulter
● Biosite Inc.
● Dade-Behring
● Roche Diagnostics
● Beckman Coulter
do Sechtem ● Bosch ● Novartis
● Pfizer
teve Steinhubl ● Eli Lily
● The Medicines Company
● AstraZeneca
● Eli Lilly
● Sanofi-Aventis
● The Medicines
Company
arco A. Tubaro None None
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presentations:
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Diagnostics
None None None None
None None None None
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